Scintigrafija somatostatinskih receptora pomoću oktreotida obilježenoga Tehnecijem-99m u bolesnika s neuroendokrinim tumorima [Somatostatin receptor scintigraphy in neuroendocrine tumour patients using Technetium-99m octreotide]

Trogrlić, Mate (2017) Scintigrafija somatostatinskih receptora pomoću oktreotida obilježenoga Tehnecijem-99m u bolesnika s neuroendokrinim tumorima [Somatostatin receptor scintigraphy in neuroendocrine tumour patients using Technetium-99m octreotide]. PhD thesis, Sveučilište u Zagrebu.

PDF Download (1MB)

Abstract

Objective: The aim of this study was to evaluate the additional value of 99mTc-HYNIC-TOC SPECT/CT over planar whole-body (WB) scintigraphy and SPECT alone in the detection and accurate localisation of neuroendocrine tumour (NET) lesions. Methods: This study included 65 patients with a definitive histological diagnosis of NET prior to scintigraphy. Planar WB scintigraphy, SPECT, and SPECT/CT images were acquired at 4 h post-administration of 670 MBq 99mTc-HYNIC-TOC. Additional SPECT images at 10 min after tracer administration were also acquired. Clinical and imaging follow-up findings were considered as the reference standards. Results: The sensitivity and specificity of SPECT/CT were found to be 88.9% and 79.3%, respectively. The diagnostic accuracies of WB scintigraphy, 4h-SPECT, and SPECT/CT were 72.3, 73.8, and 84.6%, respectively. The area under curve (AUC) value for SPECT/CT (0.84) was the highest, followed by those for 4h-SPECT (0.75) and WB scintigraphy (0.74). The accuracy and AUC values of SPECT/CT were significantly better compared to those of WB scintigraphy (P < 0.001), 10 min-SPECT (P < 0.001), and 4h-SPECT (P = 0.001). Conclusion: The sensitivity and diagnostic accuracy of SPECT/CT in the evaluation of NET lesions are higher compared to those of other tested imaging modalities.

Abstract in Croatian

Cilj: ove studije je bila evaluacija dodatne vrijednosti tehnecij-99m oktreotid SPECT/CT-a u odnosu na planarne scintigrame cijelog tijela (WB) i sam SPECT u detekciji i točnoj lokalizaciji lezija neuroendokrinih tumora. Metode:Ovo istraživanje je obuhvaćalo 65 bolesnika s patohistološki utvrđenom dijagnozom neurondokrinog tumora. Planarni scintigrami cijelog tijela, SPECT i SPECT/CT su snimljeni 4 sata nakon injiciranja 670MBq tehnecij-99m obilježenog oktreotida. Također su snimljeni i dodatni tomogrami (SPECT) 10 minuta po injiciranju radiofarmaka. Kliničko praćenje i praćenje konvencionalnim dijagnostičkim metodama je smatrano referentnim standardom. Rezultati: Osjetljivost SPECT/CT je iznosila 88.9%, a specifičnost 79.3%. Dijagnostička točnost planarnih scintigrama cijelog tijela iznosila je 72.3%, SPECT snimanja 73.8%, a SPECT/CT snimanja 84.6%. AUC vrijednost („area under curve“) je bila najviša za SPECT/CT (0.84), slijedilo je SPECT snimanje (0.75) te planarni scintigrami cijelog tijela (0.74). Dijagnostička točnost i AUC vrijednost su značajno bolje za SPECT/CT u odnosu na ostale ispitivane modalitete. Zaključak: Osjetljivost i dijagnostička točnost SPECT/CT u evaluaciji neuroendokrinih lezija je viša u odnosu na ostale ispitivane dijgnostičke modalitete.

Actions (login required)

View Item

Downloads